Finnish pharma company Orion has unveiled a new organizational structure as it pursues a strategic growth target of $1.47 billion in net sales by the end of 2025.
The new org structure as well as changes to the executive management board will take effect at the start of 2023.
As of Jan. 1, Orion will have five business divisions: Innovative Medicines (patented drugs), Branded Products (in-house developed legacy products), Generics and Consumer Health, Animal Health and Fermion (APIs).
The reorg will involve changing up Orion's executive management board, appointing several new senior vice presidents, including:
- Satu Ahomäki, appointed Senior Vice President of the Generics and Consumer Health
- Niclas Lindstedt, appointed Senior Vice President of the Animal Health
- Hao Pan, appointed Senior Vice President of the Branded Product
- Outi Vaarala, appointed Senior Vice President of the Innovative Medicines
Starting Nov. 1, the reorganized divisions will operate under the direction of the new president and CEO, Liisa Hurme, who was was named as the company lead back in April.
Back in March, Orion had announced that it would refocus its R&D on cancer and pain meds, discontinuing R&D on neurodegenerative and rare diseases — a decision that resulted in a staff reduction of 37 people.
